首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Clinical cancer research

缩写:CLIN CANCER RES

ISSN:1078-0432

e-ISSN:1557-3265

IF/分区:10.9/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引11950条
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Justin Rhoades,Anuj Patel,Kan Xiong et al. Justin Rhoades et al.
Purpose: Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment...
Nabil F Saba,Marshall Posner,Kevin Harrington et al. Nabil F Saba et al.
Purpose: STAT3 is important in promoting a pro-oncogenic tumor microenvironment. This first randomized trial of a STAT3-targeting ASO with pembrolizumab assessed whether this first-line combination would improve outcomes ...
Hanan Babeker,Emmanuel Nwangele,Alissar Monzer et al. Hanan Babeker et al.
Purpose: MUC-16-targeted antibodies can deliver contrast agents (diagnostic) and/or cytotoxic payloads (therapy) to the tumor site. MUC-16 is overexpressed in 80% of epithelial ovarian cancer (EOC) and 65% of pancreatic d...
Benedito A Carneiro,Thomas Marron,Dmitriy Zamarin et al. Benedito A Carneiro et al.
Purpose: MEDI1191 is a lipid nanoparticle-formulated mRNA designed to induce local interleukin-12 production and intensify antitumor T cell responses. We report dose-escalation results from a first-in-human, open-label, p...
Nakul M Shah,Beatriz Alvarado-Hernandez,Xinyue Chen et al. Nakul M Shah et al.
Purpose: Intrahepatic cholangiocarcinoma (iCCA) is rising in incidence and is associated with limited treatment options and poor prognosis, particularly in advanced disease. Recently, biologic strategies such as antibody-...
Matthew L Bootsma,Marina N Sharifi,Jamie M Sperger et al. Matthew L Bootsma et al.
Purpose: Circulating tumor cells (CTCs) provide a minimally invasive window into metastatic disease and treatment response, but their clinical utility has been constrained by manual, subjective, low-throughput identificat...
Adam S Fisch,Annie R Abruzzo,Samuli Eldfors et al. Adam S Fisch et al.
Purpose: HPV-associated carcinomas(HPV+cancers) account for 5% of all cancers. Circulating tumor HPV DNA(ctHPVDNA) assays for HPV+ cancer surveillance have limited prognostic utility at the time of cancer diagnosis. While...
Isabelle Galy-Fauroux,Amna Asif-Laidin,Manon Evain et al. Isabelle Galy-Fauroux et al.
Background: We aimed to identify circulating and tumor immune features predictive of oncological outcomes under Atezolizumab-Bevacizumab (AtezoBev) therapy for hepatocellular carcinoma (HCC). ...
Adel Shahnam,Mrinal M Gounder Adel Shahnam
Although BRIGHTLINE-1 was headlined as a "negative trial," brigimadlin showed clear biological activity, with median PFS of 8.4 months, ORR of 22.3%, and translational evidence of p53 reactivation. Its failure largely reflects flawed contro...